State of New York   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Albany NY United States (1788)

Organization Overview

First Clinical Trial
2000
NCT01594346
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

New York State Department of Health | New York State Institute for Basic Research | New York State Institute for Basic Research in Developmental Disabilities | NY Health d/b/a New York Cancer and Blood Specialists

Active Ingredients

Drugs in Phase 4 Trials (2)

droxidopa (northera) (1 trial)

inactivated influenza vaccine (1 trial)

Drugs in Phase 3 Trials (2)

multivitamins (1 trial)

vitamin e (2 trials)

Drugs in Phase 2 Trials (2)

levoleucovorin (fusilev) (2 trials)

propranolol (inderal) (1 trial)

Drugs in Other Trials (3)

montelukast (singulair) (1 trial)

sulfamethoxazole (gantanol) (1 trial)

trimethoprim (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 2)

Alzheimer Disease (Phase 3)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Child Development Disorders, Pervasive (Phase 2)

Developmental Disabilities (Phase 2)

Disease (Phase 2)

Down Syndrome (Phase 3)

Hypotension (Phase 4)

Hypotension, Orthostatic (Phase 4)

Language Disorders (Phase 2)

Self-Injurious Behavior (Phase 2)

Spinal Cord Injuries (Phase 4)

Syndrome (Phase 3)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 9